Nautilus Biotechnology Inc (NAUT) FinancialsNAUTNautilus Biotechnology Inc

Evaluating the bottom line, Nautilus Biotechnology, Inc. maintains a gross margin of 92.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8296.32%, while the net margin is -7615.26%. These profitability ratios, combined with a Return on Equity (ROE) of -36.21%, provide a clear picture of how effectively NAUT converts its operational activities into shareholder value.

In the context of the broader market, NAUT competes directly with industry leaders such as PRLD and CTNM. With a market capitalization of $334.68M, it holds a leading position in the sector. When comparing efficiency, NAUT's gross margin of 92.11% stands against PRLD's 100.00% and CTNM's N/A. Such benchmarking helps identify whether Nautilus Biotechnology, Inc. is trading at a premium or discount relative to its financial performance.

Nautilus has recently generated its first revenue of $190,000 in Q2 2026, marking a significant milestone. However, it continues to report substantial net losses, with a net income loss of $14.47 million in the same quarter. The gross margin of 92.11% suggests high potential profitability once it scales.